NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (NK) cell therapeutics, today announced the acceptance of an abstract for presentation on the effect of SNK01 NK cell therapy on CSF proteins, plasma proteins, and cognitive function in patients with advanced Alzheimer’s disease.

Metadata
Provider: 
GlobeNewswire, Inc.GlobeNewswire, Inc.
Retrieved on: 
Monday, March 4, 2024
Information
Tags: 
Westin Hotels & Resorts, Conference, Patient, NK, CSF, Natural killer T cell
Geotags: 
SANTA ANA, CA, US, WASHINGTON
⚠ partially generated by AI ↴
Organisation: 
NKGEN BIOTECH, NKGEN BIOTECH, INC.
Summary
Key Points: 
  • SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (NK) cell therapeutics, today announced the acceptance of an abstract for presentation on the effect of SNK01 NK cell therapy on CSF proteins, plasma proteins, and cognitive function in patients with advanced Alzheimer’s disease.
  • The data will be presented at the Tau2024 Global Conference, held March 25-26, 2024, virtually and at The Westin Washington, DC Downtown in Washington, D.C.
    For more details, please view the Conference Program at the following link: Tau2024 Global Conference .


SANTA ANA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (NK) cell therapeutics, today announced the acceptance of an abstract for presentation on the effect of SNK01 NK cell therapy on CSF proteins, plasma proteins, and cognitive function in patients with advanced Alzheimer’s disease. The data will be presented at the Tau2024 Global Conference, held March 25-26, 2024, virtually and at The Westin Washington, DC Downtown in Washington, D.C.

Presentation Details:

Abstract Title: Beneficial Effect on CSF and Plasma Tau Proteins and Cognitive Function in Alzheimer's Disease Subjects Treated with Expanded Non-Genetically Modified Autologous Natural Killer Cells (SNK01)

Authors: Clemente Humberto Zuniga Gil, Blanca Isaura Acosta Gallo, Rufino Menchaca Diaz, Cesar Alejandro Amescua, Sean Hong, Lucia Hui, Hank Lee, Juan Mata, Paul Y. Chang, Katia Betito, Paul Y. Song

Date: Monday, March 25, 2024

Time: 12:15 pm – 12:45 pm ET

For more details, please view the Conference Program at the following link: Tau2024 Global Conference.

About NKGen Biotech
NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Forward-Looking Statements

Statements contained in this press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company’s plans and expected timing for developing SNK01, including the expected timing of completing and announcing further results from its ongoing Phase 1 clinical study; and the Company’s expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors—Financial and Filings”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Internal Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Investor Relations and Corporate Communications
949-396-6830
[email protected]

External Contacts:
Chris Calabrese
Managing Director
LifeSci Advisors, LLC
[email protected]

Kevin Gardner
Managing Director
LifeSci Advisors, LLC
[email protected]


Primary Logo
Copyright: 
2024 GlobeNewswire, Inc.. All Rights Reserved.